Fido seems to be doing a lot of swing trading in their small cap bio portfolios, to rack up gains that help make up for their lack of discipline in running after and paying top dollar to buy stocks after successful study data.
The best talent at the large mutual funds has left for the upside offered by hedge operators.
I would NOT be swayed by the folks at Fido, or any other of the large mutual shops.
I'm watching the trend here as we approach release of Allovectin results. Right now over 100 institutions/funds own over 50% of shares. IMO these numbers will go up as the share price moves above $5 in coming weeks and shorts are squeezed. Time will tell.
I expect to see a solid increase in institutional ownership through 3-31 given that the big volume and price run-up was related to the 3-6 Cowan conference.
As of this morning,
IBD has a B+ Acc/Dis Rating and
an Up/Down Volume Rating of 1.4
That is encouraging.
The average volume we've seen over the last few days tells me they have a super tight lid on the "Sweep" results from late March. I thought we would see more action by now.
They may be gearing up for the 4-22 Bio conference.